Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12882766 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL919426 | 0.97 | — | — | |
| SCHEMBL330126 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5AKDM4C | |
| SCHEMBL8699546 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5AKDM4C | |
| SCHEMBL919903 | 0.92 | — | — | |
| SCHEMBL330319 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5AKDM4C | |
| SCHEMBL3026625 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5AKDM4C | |
| SCHEMBL918746 | 0.89 | SIGMAR1 (0.52) | CYP1A2SIGMAR1EPHX1KDM5AKDM4C | |
| SCHEMBL308349 | 0.85 | — | — | |
| SCHEMBL920351 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735226-B2 | Methods and devices for forming nanostructure monolayers and devices including such monolayers | SANDISK CORPORATION (US) | 2014-05-27 | — | — | US | claimed |
| US-20130337642-A1 | METHODS AND DEVICES FOR FORMING NANOSTRUCTURE MONOLAYERS AND DEVICES INCLUDING SUCH MONOLAYERS | SANDISK 3D LLC (US) | 2013-12-19 | — | — | US | claimed |
| US-8507390-B2 | Methods and devices for forming nanostructure monolayers and devices including such monolayers | SANDISK CORPORATION (US) | 2013-08-13 | — | — | US | claimed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| US-7968273-B2 | Methods and devices for forming nanostructure monolayers and devices including such monolayers | NANOSYS, INC. (US) | 2011-06-28 | — | — | US | claimed |
| US-20110034038-A1 | Methods and devices for forming nanostructure monolayers and devices including such monolayers | NANOSYS, INC. (US) | 2011-02-10 | — | — | US | claimed |
| US-20100155786-A1 | Methods and devices for forming nanostructure monolayers and devices including such monolayers | NANOSYS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | claimed |
| EP-2052407-A2 | METHODS AND DEVICES FOR FORMING NANOSTRUCTURE MONOLAYERS AND DEVICES INCLUDING SUCH MONOLAYERS | Nanosys, Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | claimed |
| US-7504446-B2 | Aqueous inks containing colored polymers | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | claimed |
| WO-2008013959-A2 | METHODS AND DEVICES FOR FORMING NANOSTRUCTURE MONOLAYERS AND DEVICES INCLUDING SUCH MONOLAYERS | NANOSYS, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | claimed |
| US-20070032091-A1 | Methods and devices for forming nanostructure monolayers and devices including such monolayers | NANOSYS, INC. (US) | 2007-02-08 | — | — | US | claimed |
| US-20060074142-A1 | Aqueous inks containing colored polymers | XEROX CORPORATION | 2006-04-06 | — | — | US | claimed |
| CN-112279864-B | Difunctional coumarin oxime ester compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-115504896-B | Acrylic formate compound for LED photopolymerization, preparation method and application thereof | 湖北固润科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-0233228-A1 | PHARMACEUTICALLY ACTIVE 2-THIOMETHYL-SUBSTITUTED-1,4-DIHYDROPYRIDINES | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1987-08-26 | — | — | EP | disclosed |
| WO-1987000836-A1 | PHARMACEUTICALLY ACTIVE 2-THIOMETHYL-SUBSTITUTED-1,4-DIHYDROPYRIDINES | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1987-02-12 | — | — | WO | disclosed |
| US-4474803-A | 7-Oxabicycloheptane substituted thio prostaglandin analogs useful in treating platelet aggregation and bronchoconstriction | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | CYP1A2 1990/4885SIGMAR1 1534/4885EPHX1 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.